Scholar Rock (NASDAQ: SRRK) is one of 116 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Scholar Rock to similar companies based on the strength of its profitability, earnings, valuation, dividends, institutional ownership, risk and analyst recommendations.
This table compares Scholar Rock and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Scholar Rock Competitors||-5,225.95%||-64.50%||-28.08%|
This table compares Scholar Rock and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Scholar Rock||$380,000.00||-$49.33 million||-7.00|
|Scholar Rock Competitors||$897.64 million||$190.34 million||-1.30|
Scholar Rock’s rivals have higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and recommmendations for Scholar Rock and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Scholar Rock Competitors||850||2821||6136||266||2.58|
Scholar Rock currently has a consensus target price of $27.33, indicating a potential upside of 23.90%. As a group, “Biological products, except diagnostic” companies have a potential upside of 36.88%. Given Scholar Rock’s rivals higher possible upside, analysts plainly believe Scholar Rock has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
51.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 48.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.3% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, an inhibitor of the activation of transforming growth factor beta-1 to treat cancers resistant to checkpoint blockade therapies. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.